Implementation and effectiveness of a care process to prioritize weight management in primary care: a stepped-wedge cluster-randomized trial.
Perreault L, Pan Q, Rodriguez C, Gritz RM, Smith PC, Kramer ES, Tolle L, Connelly L, Tietbohl C, Williams J 2nd, Holtrop JS
- DOI
- 10.1038/s41591-025-04051-5
- Record issued
- 2026-08-15
- Engine
- 7.39.0
- Exported
- 2026-09-20
Prepared by Alpha1. This document is confidential: it is intended for the recipient it was shared with and must not be redistributed. The live record at alpha1science.com/verify/b078cdc8-0252-4b2c-9284-ce04c7f5f591 is authoritative.
How this rating was calculated
- IntegrityIntegrity concern ×4−2★
- ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
- ClaimsTreatment effect not shown to be clinically meaningful−0.5★
- ReportingData & code availability partially met−0.25★
- CitationsUnresolved reference−0.25★
- 01Efficacy rests on an unvalidated surrogate endpoint
The primary efficacy claim is based on weight change, which is a surrogate endpoint for clinical outcomes such as mortality or cardiovascular events. The paper does not demonstrate target engagement at the tested dose (since it's a care process, not a drug) nor does it cite validated evidence linking weight loss to hard clinical outcomes in this context. The effect size is small (0.58 kg) and the paper itself notes it is not clinically meaningful for individual patients.
“This result should not be misinterpreted to mean that 0.58 kg is clinically meaningful to a singular patient; rather, it is urged to look beyond to its potential impact on public health.”
- 02Treatment effect not shown to be clinically meaningful
The primary reported effect is a total difference of 0.58 kg over 18 months, which is a small fraction of typical body weight and below established minimal clinically important differences for weight loss (usually 5% or 5 kg). The paper acknowledges this is not clinically meaningful for individual patients, and no anchor to clinical meaningfulness is provided.
“This result should not be misinterpreted to mean that 0.58 kg is clinically meaningful to a singular patient; rather, it is urged to look beyond to its potential impact on public health.”
- 03Other integrity concern
Trial NCT04678752 was first submitted to ClinicalTrials.gov on 2020-11-24, after the registered study start date of 2020-03-17. Retrospective registration means the protocol and outcomes were not on the public record before the study ran, which is what prospective registration exists to establish.
NCT04678752
reviewer’s wording
This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.
This is a well-conducted and transparently reported stepped-wedge cluster-randomized pragmatic trial. The main methodological strengths are the rigorous cluster randomization, detailed statistical methods, and comprehensive reporting of demographics and outcomes. The primary weakness is the vague data availability statement and lack of code sharing, which limits reproducibility.
Both reviewers agreed on all dimensions; no divergence to reconcile. The statistics verification covered only 3 tests (those with test statistics/df or effect+CI), so the paper's statistics are not fully verified. The citation check found 1 reference not found in any registry, which is a potential fabrication signal. The integrity check noted retrospective trial registration and minor internal rounding discrepancies.
Numerical inconsistencies
1 finding · worst lowValues that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.
- Internal contradictions in the reported numbersAssessed
Recomputed 3 tests: 3 consistent, 0 inconsistent; 1 recomputed directly from the reported test statistics, 2 via agent-written checks.
- CONSISTENTreported p < .001 · recomputed p = <.001Recomputed OR 1.23 (95% CI 1.16–1.31), reported p<0.001
“OR = 1.23; 95% CI 1.16, 1.31; P < 0.001”
Taken as given: 1.16–1.31 is a two-sided 95% confidence interval for the OR of 1.23, not a range, an IQR, or a different interval level; the OR is a RATIO measure, so the interval is symmetric on the log scale; p<0.001 is the p for THIS estimate, not for another comparison in the same sentenceMethod: back the two-tailed p out of the log-scale CI width and compare it against the printed pHow we recomputed it: pCI(1.23, 1.16, 1.31, 1) - CONSISTENTreported p < .001 · recomputed p = <.001Reviewers 1, 2Check p-value for the counterfactual total difference of 0.58 kg with 95% CI 0.54-0.61.
“for a total difference of 0.58 kg (95% CI: 0.54 kg, 0.61 kg; P < 0.001)”
Taken as given: The estimate is a mean difference with a two-sided 95% CI.; The CI is symmetric on the linear scale.Method: Two-tailed p-value derived from the estimate and 95% CI using a normal approximation.How we recomputed it: pCI(0.58, 0.54, 0.61, 0) - CONSISTENTreported p < .001 · recomputed p = <.001Reviewers 1, 2Check p-value for the adjusted difference of 2.36 kg with 95% CI 2.31-2.42.
“adjusted difference of 2.36 kg over 18 months; 95% CI: 2.31 kg, 2.42 kg, P < 0.001”
Taken as given: The estimate is a mean difference with a two-sided 95% CI.; The CI is symmetric on the linear scale.Method: Two-tailed p-value derived from the estimate and 95% CI using a normal approximation.How we recomputed it: pCI(2.36, 2.31, 2.42, 0)
- lowinternal contradictionIn Table 1, the 'Unknown' sex count for the 'Both phases' group is 1, but the sum of female and male counts (51,692 + 51,547 = 103,239) plus 1 equals 103,240, which is consistent. However, for the 'Usual care' group, female 18,699 + male 16,805 = 35,504, plus 1 unknown = 35,505, consistent. No issue.
“Unknown | 1 (0.0%) | 1 (0.0%) | 3 (0.0%) | 1 (0.0%) | 0 (0.0%) | 0 (0.0%)”
Table 1Find in source - lowinternal contradictionThe abstract reports a total difference of 0.58 kg, but the results section reports a total weight gain of 0.47 kg in usual care and a total weight loss of 0.10 kg in intervention, which sum to 0.57 kg, not 0.58 kg. This is a minor rounding discrepancy.
for a total difference of 0.58 kg (95% CI: 0.54 kg, 0.61 kg; P < 0.001) ... for an average total weight gain of 0.47 kg ... for an average total weight loss of 0.10 kg
Abstractreviewer’s wording - lowinternal contradictionThe average time in the intervention phase for patients receiving weight-related care is reported as 32 months, which seems inconsistent with the study period (March 2020 to March 2024) and the staggered rollout.
“the average time these patients spent in the intervention phase was 32 months”
ResultsFind in source
Overstated conclusions
2 findings · worst highConclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.
- Efficacy rests on an unvalidated surrogate endpointAssessed
- Treatment effect not shown to be clinically meaningfulAssessed
5 major claims checked against the paper's own evidence: all adequately supported.
- supportedReviewers 1, 2PATHWEIGH decreased average weight by 0.29 kg at 6 months and 0.28 kg from 6 to 18 months compared to usual care.The counterfactual analysis provides model-adjusted estimates with confidence intervals and p-values supporting these claims.Evidence: Counterfactual analysis results reported in the Abstract and Results section.
“PATHWEIGH decreased average weight by 0.29 kg (95% confidence interval (CI): 0.27 kg, 0.32 kg) from the first weight to 6 months later ( P < 0.001) and 0.28 kg (95% CI: 0.26 kg, 0.31 kg) from 6 months to 18 months ( P < 0.001)”
AbstractFind in source - supportedReviewers 1, 2PATHWEIGH increased the likelihood of receiving weight-related care by 23%.The GEE logistic model result (OR=1.23, 95% CI 1.16-1.31) directly supports this claim.Evidence: GEE logistic model result reported in Results section.
PATHWEIGH increased the likelihood of a patient receiving discernable care for their weight by 23% (odds ratio = 1.23 versus usual care; 95% CI: 1.16, 1.31; P < 0.001)
Resultsreviewer’s wording - supportedReviewers 1, 2PATHWEIGH was associated with greater weight loss for those receiving weight-related care (adjusted difference of 2.36 kg over 18 months).The adjusted difference of 2.36 kg with CI and p-value supports this claim, though it is an association, not causation.Evidence: Adjusted difference reported in Abstract and Results.
“The intervention was associated with greater weight loss for those receiving weight-related care (adjusted difference of 2.36 kg over 18 months; 95% CI: 2.31 kg, 2.42 kg, P < 0.001)”
AbstractFind in source - supportedReviewers 1, 2PATHWEIGH mitigated weight gain even when patients did not receive weight-related care (adjusted difference of 0.32 kg over 18 months).The adjusted difference of 0.32 kg with CI and p-value supports this claim.Evidence: Adjusted difference reported in Abstract and Results.
“weight gain was mitigated in the intervention even when patients did not receive weight-related care (adjusted difference of 0.32 kg over 18 months, 95% CI: 0.30 kg, 0.35 kg; P < 0.001)”
AbstractFind in source - supportedReviewers 1, 2PATHWEIGH is a pragmatic, scalable approach showing favorable impact on population weight.The trial's design and results support this conclusion, though scalability is inferred from the health system context.Evidence: Overall trial results and discussion.
“Thus, PATHWEIGH is a pragmatic, scalable approach showing favorable impact on population weight.”
AbstractFind in source
Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.
- INADEQUATESurrogate endpointThe primary efficacy claim is based on weight change, which is a surrogate endpoint for clinical outcomes such as mortality or cardiovascular events. The paper does not demonstrate target engagement at the tested dose (since it's a care process, not a drug) nor does it cite validated evidence linking weight loss to hard clinical outcomes in this context. The effect size is small (0.58 kg) and the paper itself notes it is not clinically meaningful for individual patients.
“This result should not be misinterpreted to mean that 0.58 kg is clinically meaningful to a singular patient; rather, it is urged to look beyond to its potential impact on public health.”
- INADEQUATEEffect sizeThe primary reported effect is a total difference of 0.58 kg over 18 months, which is a small fraction of typical body weight and below established minimal clinically important differences for weight loss (usually 5% or 5 kg). The paper acknowledges this is not clinically meaningful for individual patients, and no anchor to clinical meaningfulness is provided.
“This result should not be misinterpreted to mean that 0.58 kg is clinically meaningful to a singular patient; rather, it is urged to look beyond to its potential impact on public health.”
Data authenticity concerns
1 finding · worst mediumAn adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.
- Other integrity concernAssessed
4 integrity concerns flagged (0 high).
- mediumotherTrial NCT04678752 was first submitted to ClinicalTrials.gov on 2020-11-24, after the registered study start date of 2020-03-17. Retrospective registration means the protocol and outcomes were not on the public record before the study ran, which is what prospective registration exists to establish.
NCT04678752
reviewer’s wording
Reporting gaps
1 finding · worst mediumRequired detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.
- Data/code availability incompleteAssessed
The introduction cites multiple references on obesity prevalence, barriers to weight management in clinical settings, and prior primary care weight loss trials. It acknowledges limitations of prior work (e.g., highly controlled trials not representative of routine practice) and explains how the pragmatic design addresses these gaps. The hypothesis follows logically from the cited evidence.
“Obesity has been recognized as a major health issue in Westernized countries for more than three decades.”
“By randomizing on the clinic (versus patient) level, as was done in previous trials, only 6.3% of our patients were exposed to the types of interventions tested in highly controlled trials; hence, the results cannot be directly compared.”
“Our objective was to determine whether the implementation of PATHWEIGH had greater effectiveness on patient weight loss and weight maintenance compared with usual care.”
“Obesity has been recognized as a major health issue in Westernized countries for more than three decades.”
“Our objective was to determine whether the implementation of PATHWEIGH had greater effectiveness on patient weight loss and weight maintenance compared with usual care.”
“Interventions tested in primary care, specifically, have shown successful patient weight loss under conditions in which patients have been recruited into a weight loss intervention with a set curriculum and coaches – , neither of which are reminiscent of routine practice.”
Randomization was performed at the clinic level using computer-generated covariate-constrained randomization, with the method and unit clearly stated. Blinding is described (clinics unaware of sequence assignment until 3 months before implementation). The trial is registered and the protocol published. Inclusion/exclusion criteria are prespecified. Power analysis is not explicitly reported, but the large sample size and pragmatic design make it less critical; however, this is a minor gap. Outlier handling is described (BMI exclusions). Controls are inherent in the stepped-wedge design (usual care phase). Independent replication is not applicable for a single pragmatic trial.
“The ITT population under study was composed of adults (≥ 18 years) having a BMI ≥ 25 kg m 2 and were seen and weighed in one of the clinics by a primary care clinician with a national provider identifier between 17 March 2020 and 16 March 2024.”
“The ITT population under study was composed of adults (≥ 18 years) having a BMI ≥ 25 kg m 2 and were seen and weighed in one of the clinics by a primary care clinician with a national provider identifier between 17 March 2020 and 16 March 2024.”
Sex, age, race/ethnicity, insurance, weight, BMI, blood pressure, labs, and comorbidities are reported in Table 1. Both sexes are included, so sex justification is not applicable. Age and health status are reported. Species/strain and housing are not applicable for a human trial. Demographics are well-covered.
“Age (years) | 56.1 (17.2) | 51.5 (18.7) | 50.5 (18.0) | 52.8 (15.4) | 47.9 (15.8) | 49.0 (15.7)”
“Female | 51,692 (50.1%) | 18,699 (52.7%) | 34,140 (51.7%) | 27,293 (61.7%) | 3,673 (58.6%) | 11,580 (61.3%)”
“Age (years) | 56.1 (17.2) | 51.5 (18.7) | 50.5 (18.0) | 52.8 (15.4) | 47.9 (15.8) | 49.0 (15.7)”
“The demographics and health metrics of patients included in this analysis are shown in Table and are highly representative of the demographics of adults residing in Colorado.”
The study was approved by the Colorado Multiple Institutional Review Board, and a waiver of informed consent was granted because data were de-identified. This satisfies both IRB approval and informed consent handling. Regulatory compliance is implied by IRB approval, though not explicitly named; however, the IRB approval is sufficient.
“Because all data were de-identified, the study was exempt from informed consent and approved by the Colorado Multiple Institutional Review Board, including a waiver of informed consent, and the full protocol has been published .”
The intervention components are thoroughly described, including EHR customization and implementation strategies. No drugs or devices are used as investigational products; the intervention is a care process. Software (R version, packages) is identified. Antibodies, cell lines, mycoplasma, and organisms are not applicable.
“Data were collected using R v.4.4.1. Data analysis used R ImerTest 3.1-3 for the main modeling and Ime 4 1.1-35.5 for contrasts and confidence intervals.”
“Data were collected using R v.4.4.1. Data analysis used R ImerTest 3.1-3 for the main modeling and Ime 4 1.1-35.5 for contrasts and confidence intervals.”
“Customization of the EHR was one component of PATHWEIGH and included three sequential steps for patients, clinic staff and clinicians.”
Tests are named (linear mixed models, GEE logistic models, chi-square tests). Assumptions are addressed through model selection and sensitivity analyses. Exact p-values are reported throughout. Effect sizes with confidence intervals are provided. Software is identified. Data presentation includes figures and tables with per-group n. Mathematical plausibility checks: the reported percentages and counts appear consistent; no obvious arithmetic errors detected.
“PATHWEIGH decreased average weight by 0.29 kg (95% confidence interval (CI): 0.27 kg, 0.32 kg) from the first weight to 6 months later ( P < 0.001)”
“Linear mixed models were used to analyze patient weight trajectories from the index weight to all other weight measures in the usual care and intervention phases.”
“Data were collected using R v.4.4.1. Data analysis used R ImerTest 3.1-3 for the main modeling and Ime 4 1.1-35.5 for contrasts and confidence intervals.”
“Linear mixed models were used to analyze patient weight trajectories from the index weight to all other weight measures in the usual care and intervention phases.”
“PATHWEIGH decreased average weight by 0.29 kg (95% confidence interval (CI): 0.27 kg, 0.32 kg) from the first weight to 6 months later ( P < 0.001)”
“A sensitivity analysis comparing the 3-piecewise linear model (presented herein) to more flexible models using 8 or 19 pieces is provided in Extended Data Table .”
The data availability statement says 'De-identified data may be shared upon request' without specifying a mechanism, conditions, or timeframe, which is inadequate per the criteria. No repository deposit or accession numbers are provided. No code sharing is mentioned. Since the study involves patient data, repository deposit and accession numbers are not applicable, but the data availability statement should be more concrete.
“De-identified data may be shared upon request.”
“De-identified data may be shared upon request.”
The trial is registered (NCT04678752). Methods are detailed enough for replication. A reporting summary is mentioned. All outcomes are reported, including null results. Limitations are thoroughly discussed. Conclusions are proportional to the evidence. Funding and competing interests are stated.
“ClinicalTrials.gov registration: NCT04678752”
“Results from this pragmatic trial should be interpreted in light of its limitations.”
“This work was funded by the National Institutes of Health (1R18DK127003).”
“ClinicalTrials.gov registration: NCT04678752”
“Results from this pragmatic trial should be interpreted in light of its limitations.”
“This work was funded by the National Institutes of Health (1R18DK127003).”
Registered (1 ID: ClinicalTrials.gov). Reporting guideline cited: CONSORT.
Broken references and links
1 finding · worst lowReferences checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.
- References not resolvable to a published paperRecomputed
Checked 29 references by DOI: 0 verified — 1 DOI unresolved, 28 no DOI (shown, not verified).
- UNRESOLVED10.1016/s0140-6736(25Obesity and severe obesity prevalence in adults: United States, August 2021–August 2023Cited DOI does not resolve to any Crossref record.
- NO DOIGlobal, regional, and national prevalence of adult overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIMoving toward health policy that respects both science and people living with obesityNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIPrevalence and recognition of obesity and its associated comorbidities: cross-sectional analysis of electronic health record data from a large US integrated health systemNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIBaseline characteristics of PATHWEIGH: a stepped-wedge cluster randomized study for weight management in primary careNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIBarriers to providing nutrition counseling by physicians: a survey of primary care practitionersNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIManaging obesity in primary care practice: an overview with perspective from the POWER-UP studyNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIPerceptions of barriers to effective obesity care: results from the national ACTION studyNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIEquity and obesity treatment—expanding Medicaid-covered interventionsNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIChanges in diet and lifestyle and long-term weight gain in women and menNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIWeight gain over 6 years in young adults: the study of novel approaches to weight gain prevention randomized trialNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIDiffusion theory and knowledge dissemination, utilization, and integration in public healthNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIPractice-based research—“Blue Highways” on the NIH roadmapNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIComparative effectiveness of weight-loss interventions in clinical practiceNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIWeight loss in underserved patients—a cluster-randomized trialNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIRandomized trial of lifestyle modification and pharmacotherapy for obesityNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIA two-year randomized trial of obesity treatment in primary care practiceNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIPragmatic trialsNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIThe PRECIS-2 tool: designing trials that are fit for purposeNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIReduction in the incidence of type 2 diabetes with lifestyle intervention or metforminNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOICardiovascular effects of intensive lifestyle intervention in type 2 diabetesNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIChanging health-related behaviours 5: on interventions to change physician behavioursNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIChanging physician behavior with implementation intentions: closing the gap between intentions and actionsNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIPhysician motivation: listening to what pay-for-performance programs and quality improvement collaboratives are telling usNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIProfessionalism, self-regulation, and motivation: how did health care get this so wrong?No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIAssociation of COVID-19 stay-at-home orders with 1-year weight changesNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIObesity prevalence among U.S. adults during the COVID-19 pandemicNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIEffectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impactNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIPATHWEIGH, pragmatic weight management in adult patients in primary care in Colorado, USA: study protocol for a stepped wedge cluster randomized trialNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
2 data/code links checked; 2 live.
- datahttps://clinicaltrials.gov/search?cond=NCT04678752LIVEHTTP 200Resolves, but the content could not be matched to the paper.
- datahttps://www.healthdatacompass.orgLIVEHTTP 200Resolves, but the content could not be matched to the paper.
Copyediting
5 minorWording, consistency and formatting errors that need correcting before submission.
No major wording or formatting errors. 5 minor suggestions below.
5 copyedit issues flagged: mostly consistency, clarity, typo.
- MINORtypoAbstract“kg m 2”→ kg m−2Superscript formatting for BMI units.
- MINORconsistencyResults, Delivery of weight-related care“χ 2 (1) = 8.38, P = 0.004, 95% CI (5.9%, 4.9%)”→ Clarify the CI notation; likely should be a difference in proportions with CI.The CI format is unusual and may confuse readers.
- MINORclarityResults, Delivery of weight-related care“χ 2 (1) = 7.22, P = .007, 95% CI (0.6%, 0.08%)”→ Ensure consistent decimal formatting (P = 0.007) and clarify CI.Inconsistent use of leading zero in p-value.
- MINORconsistencyResults, Delivery of weight-related care“χ 2 (1) = 8.38, P = 0.004, 95% CI (5.9%, 4.9%)”→ Clarify the CI notation; it appears to be a difference in proportions.The CI format is unusual.
- MINORclarityResults, Prespecified secondary analysis among patients identified as having received discernable care for their weight“the average time these patients spent in the intervention phase was 32 months”→ Verify the duration; 32 months seems long given the study period.Potential inconsistency with the study timeline.
The published work is robust in design and reporting, but readers should weigh the retrospective trial registration and the vague data/code availability as limitations. The minor internal inconsistencies (rounding, CI notation) and the unresolved reference warrant attention but do not undermine the main conclusions.
- 1.HIGHdata codeReplace the vague data availability statement in the Data Availability section with a concrete managed-access plan, specifying a platform (e.g., Vivli) or a data access committee with conditions and a timeframe.The current 'upon request' statement is inadequate for reproducibility and does not meet the standard for patient-level data sharing.
- 2.HIGHdata codeShare the custom data processing and analysis pipeline code in a public repository (e.g., GitHub or Zenodo) with a DOI, and link it in the Data Availability section.Releasing code enhances reproducibility and is expected for a data-driven pragmatic trial.
- 3.HIGHreportingVerify and correct the reference 'Obesity and severe obesity prevalence in adults: United States, August 2021–August 2023' (DOI 10.1016/s0140-6736(25) — it was not found in any registry and may be fabricated or have an incomplete DOI.An unresolved reference is a fabrication signal that must be resolved before publication.
- 4.MEDIUMreportingAdd a power analysis or sample size justification in the Methods, even if post hoc, to strengthen the study design reporting.The absence of a power analysis is a minor gap that reviewers may question.
- 5.MEDIUMreportingExplicitly state adherence to CONSORT guidelines and provide the CONSORT checklist as supplementary material.While the paper follows CONSORT-like flow, explicit adherence improves transparency and reviewer confidence.
- 6.MEDIUMreportingClarify the retrospective registration of the trial (NCT04678752) in the manuscript, noting the registration date relative to the study start, and discuss any implications.Retrospective registration is a transparency concern that readers should be aware of.
- 7.MEDIUMstatisticsCorrect the CI notation in the Results section for the chi-square tests (e.g., '95% CI (5.9%, 4.9%)') to clearly indicate it is a difference in proportions with a proper CI format.The current notation is confusing and may mislead readers.
- 8.MEDIUMcopyeditFix the inconsistent p-value formatting in the Results section (e.g., 'P = .007' to 'P = 0.007') and ensure leading zeros are used consistently.Consistent formatting is expected in a professional manuscript.
- 9.MEDIUMcopyeditCorrect the BMI unit formatting in the Abstract from 'kg m 2' to 'kg m−2'.Proper superscript formatting is required for scientific accuracy.
- 10.MEDIUMreportingVerify the reported average time in the intervention phase (32 months) for patients receiving weight-related care, as it seems inconsistent with the study period (March 2020–March 2024) and staggered rollout.An implausible duration could indicate an error in the analysis or reporting.
- 11.LOWreportingClarify the minor rounding discrepancy between the abstract's total difference (0.58 kg) and the results section (0.47 kg gain + 0.10 kg loss = 0.57 kg).Rounding discrepancies can be easily corrected to avoid confusion.
- 12.LOWreportingClarify the role of the 'reporting summary' mentioned in the paper and ensure it is accessible to readers.Transparency about reporting checklists is important for reproducibility.
The star rating is the report’s one-glance summary. Every paper starts at 5★ and loses stars for the concrete problems the review finds — so a rating is never a vague average, it’s a running total you can read line by line under “How this rating was calculated.”
- Reporting — 8 dimensionseach dimension that fully fails−½★
- each dimension partially met−¼★
- Statistics · Integrity · Claimseach serious problem−1★
- each medium problem−½★
- Citationseach retracted or unverifiable reference−¼★
- Copyeditonly when the manuscript needs a full edit−½★
The rating never drops below 1★, and a demonstrable critical failure (an impossible statistic, a proven ethics violation) caps it at 1★ on its own — so the stars can never look healthy when the verdict is CRITICAL.
The rating draws on a panel of agents. Three independent Kaimen Rigor reviewers grade the eight dimensions below across several independent passes (the shown verdict is their majority vote — steadier than any single run), isolate the paper’s major claims and check its own evidence backs them, and flag integrity concerns. Alongside them, a citation agent resolves every reference against Crossref, OpenAlex, and Retraction Watch; a statistics agent recomputes reported tests; and rule-based checks verify that declared data/code links actually resolve. Full text is required — an abstract-only submission is not analyzed.
Graded against NIH, MDAR, ARRIVE 2.0, CONSORT, EQUATOR, and RRID guidelines. A dimension that doesn’t apply to the study type is skipped, never penalized.
This Kaimen Rigor review is model-assisted and is not a substitute for formal expert review. It complements human evaluation by surfacing potential methodological concerns — verify each finding against the source.